Money follows the heart
Bardy Diagnostics announced on 4/16/2019 that it has raised $35.5 million in Series B funding with a host of new investors. The funds will be used to further accelerate growth of its innovative P-wave focused cardiac monitoring platform and to support advanced development programs, including augmented intelligence and visualization technologies. BardyDx has several patent documents in the AI Biotech/Diagnostics sector, all directed to using artificial intelligence to either detect cardiac disorders or collect electrocardiograph data for future diagnostics. Its intellectual property may have played a role in allowing the 6-year-old company to attract the high level of investment.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…